Cost Management Insights: SG&A Expenses for Opthea Limited and Amicus Therapeutics, Inc.

Biotech SG&A Expenses: A Decade of Strategic Divergence

__timestampAmicus Therapeutics, Inc.Opthea Limited
Wednesday, January 1, 2014207170002652041
Thursday, January 1, 2015472690002361587
Friday, January 1, 2016711510004472869
Sunday, January 1, 2017886710005030957
Monday, January 1, 20181272000004988941
Tuesday, January 1, 20191698610005196412
Wednesday, January 1, 20201564070006652774
Friday, January 1, 202119271000018418247
Saturday, January 1, 202221304100024827066
Sunday, January 1, 202327527000041896408
Monday, January 1, 202415488619
Loading chart...

Infusing magic into the data realm

Navigating SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing costs is crucial for success. This chart provides a fascinating insight into the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and Amicus Therapeutics, Inc. over the past decade. From 2014 to 2023, Amicus Therapeutics has seen a staggering increase in SG&A expenses, growing by over 1,200%, peaking in 2023. In contrast, Opthea Limited's expenses have grown more modestly, with a notable spike in 2023, reaching nearly 42 million. This divergence highlights the different strategic approaches these companies have taken in managing their operational costs. While Amicus Therapeutics has consistently ramped up its spending, Opthea Limited has maintained a more conservative trajectory, with a significant jump in recent years. Understanding these trends can provide valuable insights into each company's operational strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025